Android app on Google Play

Cleveland BioLabs (CBLI), Panacela Labs Receive $4.6M Contract in Russia for Xenomycins Development

November 27, 2012 7:07 AM EST Send to a Friend
Cleveland BioLabs, Inc. (Nasdaq: CBLI) and Panacela Labs, Inc. announced award of a contract valued at 146 million rubles, or approximately $4.6 million (based on current exchange rates), with the Ministry of Industry and Trade of the Russian Federation for development of Xenomycins, a family of compounds in development as anti-infective agents. The contract, issued under the Russian Federation's "Pharma 2020" development initiative, provides matching funding over a period of approximately three years, which will be used to support preclinical and clinical studies.

You May Also Be Interested In

Related Categories

Corporate News, FDA

Add Your Comment